Novo Nordisk A/S Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | $5.22 | $5.22 | $5.22 |
| Q2 2024 | 1 | $4.91 | $4.91 | $4.91 |
| Q3 2024 | 1 | $5.82 | $5.93 | $5.87 |
| Q4 2024 | 3 | $5.86 | $6.33 | $6.06 |
| Q1 2025 | 1 | $6.10 | $6.77 | $6.49 |
| Q2 2025 | 1 | $6.11 | $6.77 | $6.50 |
| Q3 2025 | 1 | $6.67 | $7.39 | $7.10 |
| Q4 2025 | 1 | $6.74 | $7.47 | $7.17 |
Novo Nordisk A/S Earnings Date And Information
Novo Nordisk A/S last posted its earnings results on Wednesday, November 6th, 2024. The company reported $0.9 earnings per share for the quarter, missing analysts' consensus estimates of $0.91 by $0.01. The company had revenue of 71.31 B for the quarter and had revenue of 232.26 B for the year. Novo Nordisk A/S has generated $19 earnings per share over the last year ($18.62 diluted earnings per share) and currently has a price-to-earnings ratio of 35.31. Novo Nordisk A/S has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, January 29th, 2025 based on prior year's report dates.
Novo Nordisk A/S Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 09/30/2024 | Q3 2024 | $6.13 | $70.57 B | $71.31 B | ||
| 06/28/2024 | Q2 2024 | $4.49 | $69.28 B | $68.06 B | ||
| 03/30/2024 | Q1 2024 | $5.70 | $65.35 B | |||
| 01/31/2024 | Q4 2023 | $0.66 | $4.92 | 4.26 | $65.86 B | |
| 09/29/2023 | Q3 2023 | $5.02 | $57.80 B | $58.73 B | ||
| 06/30/2023 | Q2 2023 | $4.33 | $56.03 B | $54.30 B | ||
| 04/13/2023 | Q1 2023 | $4.40 | $53.37 B | |||
| 02/01/2023 | Q4 2022 | $0.41 | $3.02 | 2.61 | $48.09 B | |
| 09/29/2022 | Q3 2022 | $3.18 | $44.89 B | $45.57 B | ||
| 06/29/2022 | Q2 2022 | $2.93 | $40.76 B | $41.27 B | ||
| 03/30/2022 | Q1 2022 | $3.12 | $42.03 B | |||
| 02/02/2022 | Q4 2021 | $0.36 | $2.38 | 2.02 | $38.33 B | |
| 09/29/2021 | Q3 2021 | $2.64 | $34.56 B | $35.62 B | ||
| 06/29/2021 | Q2 2021 | $2.63 | $32.35 B | $33.04 B | ||
| 03/30/2021 | Q1 2021 | $5.47 | $33.80 B | |||
| 02/03/2021 | Q4 2020 | $0.30 | $4.00 | 3.7 | $32.14 B | |
| 09/29/2020 | Q3 2020 | $4.42 | $30.93 B | $30.93 B | ||
| 06/29/2020 | Q2 2020 | $4.54 | $31.52 B | $30.01 B | ||
| 03/30/2020 | Q1 2020 | $5.07 | $33.88 B | |||
| 02/05/2020 | Q4 2019 | $0.28 | $3.68 | 3.4 | $32.42 B |
Novo Nordisk A/S Earnings: Frequently Asked Questions
-
When is Novo Nordisk A/S's earnings date?
Novo Nordisk A/S has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, January 29th, 2025 based off last year's report dates.
-
How can I listen to Novo Nordisk A/S's earnings conference call?
The conference call for Novo Nordisk A/S's latest earnings report can be listened to online.
-
How can I read Novo Nordisk A/S's conference call transcript?
The conference call transcript for Novo Nordisk A/S's latest earnings report can be read online.
-
How much revenue does Novo Nordisk A/S generate each year?
Novo Nordisk A/S (:NVO) has a recorded annual revenue of $232.26 B.
-
How much profit does Novo Nordisk A/S generate each year?
Novo Nordisk A/S (:NVO) has a recorded net income of $232.26 B. Novo Nordisk A/S has generated $18.62 earnings per share over the last four quarters.
-
What is Novo Nordisk A/S's price-to-earnings ratio?
Novo Nordisk A/S (:NVO) has a price-to-earnings ratio of 35.31 and price/earnings-to-growth ratio is 6.41.
